Letter: Rebound hypertension after acute methyldopa withdrawal.
نویسندگان
چکیده
منابع مشابه
Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
BACKGROUND The oral sphingosine-1-phosphate receptor modulator fingolimod (FTY720) was recently approved for the treatment of relapsing-remitting multiple sclerosis. To date, data about a possible recurrence of disease activity after discontinuation of fingolimod treatment are scarce. OBJECTIVE To describe a patient who discontinued fingolimod treatment after a local malignant melanoma was di...
متن کاملPersistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena.
OBJECTIVE To describe tardive rebound anxiety phenomena (panic, anxiety and insomnia) following abrupt paroxetine discontinuation. METHOD Case report, with comprehensive literature review on rebound and withdrawal phenomena associated with psychotropic medications. RESULTS Three different discontinuation syndromes with psychotropics are described: (1) new-onset CNS-depressant type withdrawa...
متن کاملClopidogrel withdrawal: is there a "rebound" phenomenon?
Dual antiplatelet therapy with aspirin and clopidogrel is routinely indicated in patients with acute coronary syndromes and following percutaneous coronary intervention to reduce the risk of cardiovascular mortality and ischaemic events. Although clinical guidelines recommend aspirin lifelong and clopidogrel for between one and 12 months, depending upon the indication, the optimal duration of c...
متن کاملMethyldopa in the Treatment of Hypertension.
S ISCE t,he initial comm~~ni~ation of Oates etall reporting that methyldopa lowered blood pressure in hypertensive patients additional studies hal-e attested to the efficacy of this drug as an antihypertensi~e agent.‘-? Over the past 21/ years methyldopa (Aldome@) has been utilized in this clinic usuaily in conjunction with sulfonamide saluretic agents in the long-term treatment of hypertensive...
متن کاملHypertensive rebound after angiotensin converting enzyme inhibitor withdrawal in diabetic patients with chronic renal failure.
Sir, Although angiotensin-converting enzyme (ACE) inhibitors are considered a milestone in the treatment of hypertension and microalbuminuria in diabetic patients w1,2x, some cau-tionary notes were reported in the setting of signi®cant reduction of renal function w3±5x. Discrepancy between long-term trials w1,2x and anecdotal reports w3±5x is probably due to the different selection of patients ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1976
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.2.6031.367-b